PRT13722 / Prelude Therap - LARVOL DELTA

First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved pre-clinical hematological safety profile (AACR 2026) - "Targeting KAT6 has recently been clinically validated in ER+/HER2- breast cancer (BC) and is being evaluated in Phase 3 trials in combination with fulvestrant (FUL). In summary, our first-in-class potent and selective oral KAT6A degrader, PRT13722, demonstrates improved efficacy and the potential for reduced off-target neutropenia compared to certain clinically validated KAT6A/B dual inhibitors. IND filing for PRT13722 is on track for mid-2026."

Monotherapy • Preclinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2 • KAT6A • KAT6B • PIK3CA

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting (GlobeNewswire) - "'We expect to file an IND in the middle of this year and enter clinical trials in the second half of 2026'."

IND • Preclinical • Solid Tumor

Highly selective KAT6A oral degrader program (GlobeNewswire) - "The Company has selected a development candidate and remains on track to file an IND in mid-2026 with phase 1 study initiation planned in the 2nd half of 2026."

IND • New P1 trial • Estrogen Receptor Positive Breast Cancer

Highly selective KAT6A oral degrader program (GlobeNewswire) - "The Company has selected a development candidate and is on track to file an IND in mid-2026 and initiate a phase 1 dose escalation study in the second half of 2026."

IND • New P1 trial • Estrogen Receptor Positive Breast Cancer

Highly selective KAT6A oral degrader program (GlobeNewswire) - "The Company is now advancing a development candidate and remains on track to file an IND in the first half of 2026."

IND • Estrogen Receptor Positive Breast Cancer • Solid Tumor

Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate anti-cancer activity in pre-clinical models (AACR 2025) - "Lastly, we utilized a predictive assay for neutropenia (CFU-GM), where we found KAT6A-selective degraders were inactive, in contrast to KAT6A/B inhibitors. Our first-in-class KAT6A degraders demonstrated proof-of-concept for a differentiated strategy with potential to improve the depth of response and safety profile for a clinically active anti-cancer target."

Preclinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Oncology • Solid Tumor • ER • HER-2 • KAT6A • KAT6B